McDermott Will & Schulte

McDermott Will & Schulte advises on IP, regulatory, transactional, and litigation matters relating to life sciences at a national and international level. Its client base includes internationally recognized life sciences companies in healthcare, life sciences, pharma, and biotech. The team advises clients on matters across all phases of product development, with vast experience acting as regulatory counsel in legislative compliance and strategies. The practice stands out for its strong IP experience, including patent building, maintenance, enforcement, and prosecution. It currently represents Alnylam Pharmaceuticals in infringement lawsuits against Moderna and Pfizer/BioNTech regarding their COVID-19 vaccines, with Sarah Chapin Columbia being one of the lead partners. Silicon Valley’s Judy Mohr also serves as IP counsel to QuidelOrtho Corporation regarding corporate transactions and its patent estate. The practice is co-headed by Douglas Carsten and James Ravitz, who focus on intellectual property and FDA regulations, respectively. Kristian Werling, transactions specialist, and Byron Kalogerou, who founded the firm’s life sciences practice, are the firm’s key corporate matters experts. First chair litigator Michael Sitzman joined the practice in November 2024 from DLA Piper LLP (US).